Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Latest From Gubra ApS

Boehringer Ingelheim, Gubra Enter Third Obesity Deal

The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.

Companies Commercial

Boehringer Adds Yuhan’s First-In-Class Dual Agonist To NASH Portfolio

Yuhan reaches $870m NASH licensing-out deal with Boehringer, touting its competitiveness in the space after earlier alliance with Gilead. The collaboration for first-in-class GLP-1/FGF21 dual agonist is poised to beef up German firm's R&D expertise in cardiometabolic disease.

South Korea Deals

Deal Watch: Vertex Expands Gene-Editing Efforts With A Pair Of Deals

CF-focused Vertex will buy Exonics and expand a collaboration with CRISPR Therapeutics, with plans to develop therapies for DMD and myotonic dystrophy type 1. Merck acquires TGFβ-focused Tilos, while Achaogen offloads most of its assets at auction.

Deals Business Strategies

BI Inks Second Obesity Pact With Denmark’s Gubra

The German group has signed a second deal with Gubra to develop poly-agonist peptides for obesity that could be worth up to €240m.

Metabolic Disorders Companies
See All

Company Information

  • Industry
  • Contract Research Organization-CRO
  • Pharmaceuticals
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
UsernamePublicRestriction

Register